| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $249,121 | 1 | 100 |
| Chivukula Pad | Chief Scientific Officer & COO | 0 | $0 | 1 | $249,121 | $-249,121 |
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Arcturus Therapeutics Holdings Inc. have bought $0 and sold $249,121 worth of Arcturus Therapeutics Holdings Inc. stock.
On average, over the past 5 years, insiders at Arcturus Therapeutics Holdings Inc. have bought $122,546 and sold $27.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,222 shares for transaction amount of $39,996 was made by Marquet Magda (director) on 2022‑12‑15.
| 2024-10-15 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 12,000 0.0423% | $20.76 | $249,121 | -23.41% | |
| 2024-06-12 | Sale | SASSINE ANDY | Chief Financial Officer | 50,000 0.1838% | $32.03 | $1.6M | -42.95% | |
| 2024-06-05 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 114 0.0004% | $45.00 | $5,130 | -59.64% | |
| 2024-06-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 26,000 0.095% | $40.01 | $1.04M | -55.87% | |
| 2024-03-25 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 17,435 0.0652% | $35.02 | $610,574 | -40.76% | |
| 2024-03-19 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 8,565 0.033% | $35.01 | $299,839 | -38.71% | |
| 2023-11-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $18.72 | $93,602 | +40.76% | |
| 2023-10-02 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0188% | $25.61 | $128,062 | +2.96% | |
| 2023-09-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $31.45 | $157,264 | -13.91% | |
| 2023-08-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0184% | $34.91 | $174,550 | -15.95% | |
| 2023-07-14 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 25,000 0.093% | $35.01 | $875,250 | -13.94% | |
| 2023-07-14 | Sale | Kummerfeld Keith C | See Remarks | 6,968 0.0259% | $35.00 | $243,880 | -13.94% | |
| 2023-07-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0189% | $28.75 | $143,750 | +7.43% | |
| 2023-06-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0189% | $27.16 | $135,800 | +11.30% | |
| 2023-05-11 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 7,925 0.0279% | $30.24 | $239,652 | -9.46% | |
| 2023-05-10 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 17,075 0.0656% | $30.00 | $512,250 | -0.36% | |
| 2023-05-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $25.93 | $129,650 | +12.31% | |
| 2023-04-18 | Sale | Kummerfeld Keith C | See Remarks | 6,968 0.0265% | $28.18 | $196,358 | +5.22% | |
| 2023-04-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0186% | $25.38 | $126,900 | +11.56% | |
| 2023-03-06 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0191% | $16.07 | $80,350 | +75.98% |
| Chivukula Pad | Chief Scientific Officer & COO | 435334 1.6052% | $5.39M | 0 | 32 | |
| Payne Joseph E | President and CEO | 1480097 5.4575% | $18.32M | 3 | 0 | +43.7% |
| Ultragenyx Pharmaceutical Inc. | director | 1400000 5.1621% | $17.33M | 0 | 4 | |
| SASSINE ANDY | Chief Financial Officer | 220526 0.8131% | $2.73M | 4 | 1 | +172.25% |
| FARRELL PETER C | director | 42955 0.1584% | $531,782.90 | 2 | 0 | +21.56% |
| Marquet Magda | director | 24942 0.092% | $308,781.96 | 2 | 0 | +34.72% |
| Kummerfeld Keith C | See Remarks | 950 0.0035% | $11,761.00 | 2 | 2 | +40.68% |
$21,797,027 | 94 | 5.08% | $359.18M | |
$99,438,720 | 81 | 6.74% | $323.11M | |
$14,527,743 | 76 | 38.40% | $381.97M | |
$5,911,307 | 70 | -1.38% | $307.72M | |
$41,446,394 | 27 | 12.91% | $333.26M | |
$56,593,094 | 24 | 46.48% | $338.87M | |
$3,668,031 | 23 | 1.97% | $315.13M | |
$2,484,989 | 17 | -17.86% | $330M | |
$46,442,839 | 15 | -20.05% | $367.63M | |
$104,137,421 | 15 | 21.28% | $315.67M | |
$7,254,955 | 14 | 20.70% | $366.74M | |
$70,704,995 | 14 | 67.19% | $366.84M | |
Arcturus Therapeutics Holdings Inc. (ARCT) | $1,037,470 | 13 | 78.00% | $335.75M |
$81,667,942 | 12 | -57.54% | $354.61M | |
$19,659,196 | 11 | 21.81% | $369.76M | |
$4,706,376 | 8 | 42.30% | $306.67M | |
$335,001 | 6 | -23.71% | $306.4M | |
$79,246,559 | 5 | -27.73% | $349.59M | |
$51,588,185 | 5 | 19.18% | $322.8M |
| Increased Positions | 68 | +37.99% | 2M | +8.47% |
| Decreased Positions | 76 | -42.46% | 2M | -8.45% |
| New Positions | 22 | New | 1M | New |
| Sold Out Positions | 26 | Sold Out | 941,826 | Sold Out |
| Total Postitions | 171 | -4.47% | 27M | +0.03% |
| Federated Hermes, Inc. | $60,225.00 | 17.39% | 4.69M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $35,410.00 | 10.22% | 2.76M | -229,631 | -7.68% | 2025-03-31 |
| Nikko Asset Management Americas, Inc. | $26,495.00 | 7.65% | 2.07M | -250,244 | -10.81% | 2024-12-31 |
| Ark Investment Management Llc | $24,811.00 | 7.16% | 1.93M | -167,187 | -7.96% | 2024-12-31 |
| Sumitomo Mitsui Trust Group, Inc. | $24,712.00 | 7.13% | 1.93M | -138,966 | -6.73% | 2025-03-31 |
| Vanguard Group Inc | $21,613.00 | 6.24% | 1.68M | +107,635 | +6.83% | 2024-12-31 |
| State Street Corp | $17,015.00 | 4.91% | 1.33M | -146,797 | -9.97% | 2024-12-31 |
| Schonfeld Strategic Advisors Llc | $10,894.00 | 3.15% | 849,081 | +479,482 | +129.73% | 2024-12-31 |
| Woodline Partners Lp | $10,353.00 | 2.99% | 806,912 | +26,956 | +3.46% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $9,076.00 | 2.62% | 707,404 | -85,196 | -10.75% | 2024-12-31 |